Bromodomain-containing protein 4 (BRD4)

Where the papers sit

18 papers from the last 6 months study Bromodomain-containing protein 4 (BRD4) directly · updated from PubMed 12 Oct 2026

• BRD4 Protein Degradation

  BRD4 degradation is moving from standalone PROTACs toward targeted, multifunctional delivery systems. Nanoassemblies, antibody and oncolytic-virus conjugates, and in situ synthesis pair degradation with immunotherapy, radiosensitization or phototherapy. GID4-recruiting designs address resistance caused by CRBN or VHL deficiency, while new linkers and indirect VHL recruitment expand degrader engineering. The work remains largely preclinical, with applications spanning cancer and idiopathic pulmonary fibrosis.

  11 papers · 61.1%

• Small-Molecule BRD4 Targeting

  Small-molecule BRD4 targeting is being explored through dual inhibitors, epigenetic combinations and improved compound-design tools. CDK8/BRD4 inhibitors aim to couple transcriptional control with kinase blockade, while HDAC inhibition redistributes RNA polymerase II and sensitizes pancreatic tumors to DNA damage. BRD2/BRD4 inhibition also suppresses LANA translation in KSHV-infected endothelial cells. Nanopore complex analysis and generative chemistry broaden the discovery toolkit, but the cluster offers no single validated clinical direction.

  5 papers · 27.8%

• Super-Enhancer Cancer Vulnerabilities

  Super-enhancer biology is being used to expose treatment vulnerabilities rather than simply describe oncogenic transcription. In acute megakaryoblastic leukemia, BRD4-linked regulation of PIM1 is a candidate dependency. In glioblastoma, circMLB-associated super-enhancer signaling and stress-granule assembly are tied to temozolomide resistance. The open question is whether disrupting these dependencies can overcome resistance without broad transcriptional toxicity.

  2 papers · 11.1%